VTE Risk Model in Children and a Novel Tri-specific T-cell-engager for MM

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Julie Jaffray and Ulrike Philippar on their latest articles published in Blood . Dr. Jaffray discusses her CME article, " Multisite validation of a venous thrombosis risk model in critically ill children through the CHAT Consortium ", identifying patients with risks as high as 17% and taking research one step closer to the goal of personalized thromboprophylaxis for safe and effective care of high-risk children. Dr. Philippar discusses her article " Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models ", where the extensive in vitro and in vivo preclinical studies with cell lines and patient samples indicate strong potential for this agent to have efficacy against MM expressing either or both of these antigens.

You can listen to VTE Risk Model in Children and a Novel Tri-specific T-cell-engager for MM online on Radio and Podcast. Open the player on this page to stream the available audio.

VTE Risk Model in Children and a Novel Tri-specific T-cell-engager for MM is an episode from Blood Podcast by American Society of Hematology.

This episode is 17:01 long.

This episode was published on Feb 19, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Blood Podcast when more episodes are available from the podcast feed.